Last reviewed · How we verify
NCT03797482: Hypoxia
A Prospective Evaluation of the Peri-operative Hypoxia in Breast Cancer
trial testing Intra-operative Tumor Tissue Biopsy in Breast Cancer Female in 500 participants. Currently enrolling.
30 September 2025
Quick facts
| Lead sponsor | Tata Memorial Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 27 November 2017 |
| Primary completion | 30 September 2025 |
| Estimated completion | 30 November 2025 |
| Sites | 1 location across India |
Drugs / interventions tested
- Intra-operative Tumor Tissue Biopsy
Conditions studied
- Breast Cancer Female — all drugs for Breast Cancer Female →
Sponsor
Tata Memorial Hospital
Who can join
18 and older, female only, with Breast Cancer Female. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To understand the effects induced by acute hypoxia that sets in during surgery in breast cancer. To study this, clinical samples (Tumor biopsies) will be obtained during the surgery after partial devascularisation (sample B) and stored for future genomic and proteonomic evaluations.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Surgical Tumor Resection Deregulates Hallmarks of Cancer in Resected Tissue and the Surrounding Microenvironment.
Chaubal R, Gardi N, Joshi S, Pantvaidya G, et al · · 2024 · cited 1× · PMID 38394149 · DOI 10.1158/1541-7786.mcr-23-0265 -
Clinically actionable alterations in Indian breast cancer patients derived through whole transcriptome sequencing.
Gardi N, Chaubal R, Gandhi KA, Kadam A, et al · · 2026 · PMID 41934415 · DOI 10.25259/ijmr_1642_2024
Verify or expand the search:
- PubMed search for NCT03797482
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Female
Currently open trials in the same condition.
- NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
- NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
- NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
- NCT07214883 — UCF MammoChat: Image Repository · recruiting
- NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting
Other Tata Memorial Hospital trials
Trials by the same sponsor.
- NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
- NCT07196033 — Asian Gynecological Brachytherapy Registry in Cervical Cancer · recruiting
- NCT06804135 — Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer · recruiting
- NCT07435623 — Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study · recruiting
- NCT07342231 — FAPi PET in Pancreatic Ductal Adenocarcinoma · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03797482 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tata Memorial Hospital
- Last refreshed: 10 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03797482.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing